Αποτελέσματα Αναζήτησης
13 Δεκ 2010 · The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy. It demonstrated a significant improvement in overall survival from 11.1 months in the placebo group to 12.3 months in patients receiving maintenance erlotinib, with the important caveat ...
15 Οκτ 2010 · In the phase III SequentiAl Tarceva® in UnResectable NSCLC (SATURN; BO18192) study, maintenance therapy with erlotinib significantly increased progression-free and overall survival (PFS and OS) versus placebo in both the overall intention-to-treat (ITT) population and in patients with EGFR immunohistochemistry (IHC)-positive tumours . These ...
Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account.
The Sequential Tarceva in Unresectable NSCLC (SATURN) trial was designed to investigate the effectiveness of maintenance erlotinib treatment until the time of progression, with the goal of prolonging overall survival and delaying disease progression .
21 Αυγ 2009 · According to data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial, which was presented at the 13th World Conference on Lung Cancer, maintenance therapy with erlotinib improved overall survival in patients with advanced NSCLC after initially successful chemotherapy.
23 Απρ 2018 · The controlled phase III trial SATURN demonstrated that maintenance therapy with erlotinib after the first-line platinum-based chemotherapy prolonged progression-free survival (PFS) and overall survival (OS) of non-small cell lung cancer (NSCLC) patients with advanced, non-progressive disease.
1 Δεκ 2010 · The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy.
